NCT04400474 2025-06-19
CABATEN
Grupo Espanol de Tumores Neuroendocrinos
Phase 2 Completed
Clinical Trials
14 trialsNCT03176693 2023-11-20
Preoperative Alpha Blockade for Pheochromocytoma
University of California, Los Angeles
Phase 3 Completed
NCT02186678 2023-04-06
DOTATATE
Assistance Publique Hopitaux De Marseille
Phase NA Completed
NCT00442533 2023-04-03
Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors
Radio Isotope Therapy of America
Phase 2/3 Completed
NCT01371201 2022-08-04
FIRSTMAPPP
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Completed
NCT01967576 2021-01-06
Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01347307 2020-06-18
Stereotactic Body Radiotherapy for Spine Tumors
Mercy Research
Phase NA Completed
NCT02672020 2019-09-24
COMETETACTIC
Assistance Publique - Hôpitaux de Paris
Phase NA Completed
NCT01560260 2018-09-21
Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors
National Cancer Institute (NCI)
Phase 2 Completed
NCT01413503 2018-09-18
A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related Tumors
University of California, San Francisco
Phase 2 Completed
NCT01204476 2016-07-15
Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma
National Cancer Institute (NCI)
Phase 1 Completed
NCT00458952 2016-07-13
Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma
Molecular Insight Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT00188019 2015-07-23
Hereditary Paraganglioma: Evaluation of Screening Methods to Detect Tumors in SDH Positive Carriers
University Hospital, Angers
Phase NA Completed
NCT00339131 2011-10-12
ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma, Paraganglioma, or Metastatic Carcinoid
Molecular Insight Pharmaceuticals, Inc.
Phase 1 Completed